GlaxoSmithKline CEO Emma Walmsley has been predicting big things for respiratory triple therapy Trelegy in the next couple of years and has new data that could open up a new market.
AstraZeneca’s Fasenra (benralizumab) has seen its fortunes reverse after NICE approved the drug for severe eosinophilic asthma – broadening its recommendations for the drug’s use and giving
The US regulator has approved Sanofi/Regeneron’s Dupixent (dupilumab) in a new asthma indication, a key step in the companies attempt to build a blockbuster franchise around the drug.
Trials of Sanofi and Regeneron’s drug Dupixent (dupilumab) have shown positive results for treating patients suffering from chronic rhinosinusitis with nasal polyps, teeing up a potential n